David Ghiyam

A study appeared in the New York Times yesterday, it was reviewed in the New York Times yesterday, talking about how the most popular drug that targets this beta amyloid that accumulates in the brain is quite threatening, that about 28% of people given the drug have small brain hemorrhages.

A study appeared in the New York Times yesterday, it was reviewed in the New York Times yesterday, talking about how the most popular drug that targets this beta amyloid that accumulates in the brain is quite threatening, that about 28% of people given the drug have small brain hemorrhages.

but that people who carry a certain genetic predisposition for Alzheimer's are at a significantly increased risk for these bleeds in their brain. And what the New York Times article reported yesterday is that the company knew it. Wow. And went ahead with the research.

but that people who carry a certain genetic predisposition for Alzheimer's are at a significantly increased risk for these bleeds in their brain. And what the New York Times article reported yesterday is that the company knew it. Wow. And went ahead with the research.

So, you know, it to me violates the most important doctrine of medicine, above all, do no harm.

So, you know, it to me violates the most important doctrine of medicine, above all, do no harm.

That's right, so you were distracted by all of those graphics. All the video that's really showing this person now resuming their life, they can wear a bathing suit because their skin is cleared up. And it lowers your risk of, I mean, increases your risk of infection, including tuberculosis. And in fact, you may even die. You're right.

That's right, so you were distracted by all of those graphics. All the video that's really showing this person now resuming their life, they can wear a bathing suit because their skin is cleared up. And it lowers your risk of, I mean, increases your risk of infection, including tuberculosis. And in fact, you may even die. You're right.

But you're looking at this person who could finally take off his shirt. And, you know, it looks great to me.

But you're looking at this person who could finally take off his shirt. And, you know, it looks great to me.

Lewis, respectfully, it may not be the mission. I mean, I think oftentimes what we see is more interest in shareholders than stakeholders, basically that focus on the bottom line. And there was a resounding rejection of the approval process of a certain so-called Alzheimer's drug called Lekembe, still being, you know, editorials are written, why was this drug approved?

Lewis, respectfully, it may not be the mission. I mean, I think oftentimes what we see is more interest in shareholders than stakeholders, basically that focus on the bottom line. And there was a resounding rejection of the approval process of a certain so-called Alzheimer's drug called Lekembe, still being, you know, editorials are written, why was this drug approved?

Because its clinical effectiveness after 18 months is minimal at best, and the side effect profile is very scary. So as we look at the risk-benefit ratio, it doesn't add up.

Because its clinical effectiveness after 18 months is minimal at best, and the side effect profile is very scary. So as we look at the risk-benefit ratio, it doesn't add up.

I'd say it's close to 70 to 80% are either overweight or obese. Really? In fact, north of 90% of Americans have at least one component of metabolic dysfunction. And obesity is a big... Obesity, overweight, obesity is one of them. Certainly hypertension, elevated blood sugar, insulin resistance. These are all things that we consider. I add elevated uric acid to the equation as well.

I'd say it's close to 70 to 80% are either overweight or obese. Really? In fact, north of 90% of Americans have at least one component of metabolic dysfunction. And obesity is a big... Obesity, overweight, obesity is one of them. Certainly hypertension, elevated blood sugar, insulin resistance. These are all things that we consider. I add elevated uric acid to the equation as well.

This lipidemia or problems, abnormal lab studies as relates to our blood lipids. But having said that, only one or less than one in 10 individuals is metabolically intact in America today. And it's these metabolic issues that set the stage for all the things we don't want to get, including Alzheimer's disease.

This lipidemia or problems, abnormal lab studies as relates to our blood lipids. But having said that, only one or less than one in 10 individuals is metabolically intact in America today. And it's these metabolic issues that set the stage for all the things we don't want to get, including Alzheimer's disease.

You mean of using the drug?

You mean of using the drug?